HRP20100227T1 - Stanice domaćini tumora preuređene da proizvode ligand koji inducira apoptozu povezanu s faktorom nekroze tumora (trail) - Google Patents

Stanice domaćini tumora preuređene da proizvode ligand koji inducira apoptozu povezanu s faktorom nekroze tumora (trail) Download PDF

Info

Publication number
HRP20100227T1
HRP20100227T1 HR20100227T HRP20100227T HRP20100227T1 HR P20100227 T1 HRP20100227 T1 HR P20100227T1 HR 20100227 T HR20100227 T HR 20100227T HR P20100227 T HRP20100227 T HR P20100227T HR P20100227 T1 HRP20100227 T1 HR P20100227T1
Authority
HR
Croatia
Prior art keywords
cells
tumor
necrosis factor
tumor necrosis
trail
Prior art date
Application number
HR20100227T
Other languages
English (en)
Croatian (hr)
Inventor
M. Gianni Alessandro
Carlo-Stella Carmelo
Colotta Francesco
Original Assignee
Dompe' S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe' S.P.A. filed Critical Dompe' S.P.A.
Publication of HRP20100227T1 publication Critical patent/HRP20100227T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464436—Cytokines
    • A61K39/464438—Tumor necrosis factors [TNF], CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HR20100227T 2004-07-29 2010-04-19 Stanice domaćini tumora preuređene da proizvode ligand koji inducira apoptozu povezanu s faktorom nekroze tumora (trail) HRP20100227T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04017907A EP1621550A1 (en) 2004-07-29 2004-07-29 Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
PCT/EP2005/007957 WO2006010558A1 (en) 2004-07-29 2005-07-21 Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (trail)

Publications (1)

Publication Number Publication Date
HRP20100227T1 true HRP20100227T1 (hr) 2010-07-31

Family

ID=34925971

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100227T HRP20100227T1 (hr) 2004-07-29 2010-04-19 Stanice domaćini tumora preuređene da proizvode ligand koji inducira apoptozu povezanu s faktorom nekroze tumora (trail)

Country Status (25)

Country Link
US (1) US20070264231A1 (ja)
EP (2) EP1621550A1 (ja)
JP (1) JP5042826B2 (ja)
KR (1) KR20070047757A (ja)
CN (1) CN101076540B (ja)
AT (1) ATE455847T1 (ja)
AU (1) AU2005266543B2 (ja)
BR (1) BRPI0513855A (ja)
CA (1) CA2571426A1 (ja)
DE (1) DE602005019050D1 (ja)
DK (1) DK1771468T3 (ja)
ES (1) ES2340400T3 (ja)
HK (1) HK1110874A1 (ja)
HR (1) HRP20100227T1 (ja)
IL (1) IL180233A (ja)
MX (1) MX2007001152A (ja)
NO (1) NO20070956L (ja)
NZ (1) NZ552223A (ja)
PL (1) PL1771468T3 (ja)
PT (1) PT1771468E (ja)
RS (1) RS51381B (ja)
RU (1) RU2390558C2 (ja)
SI (1) SI1771468T1 (ja)
WO (1) WO2006010558A1 (ja)
ZA (1) ZA200701231B (ja)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080199423A1 (en) * 2004-06-18 2008-08-21 Genentech, Inc. Methods of Using Apo2l Receptor Agonists and Ink Cell Activators
DE102006020307A1 (de) * 2006-05-03 2007-11-08 Martin-Luther-Universität Halle-Wittenberg TNF-related apoptosis-including (TRAIL)stabil transgen exprimierende mesenchymale Stammzellen, Verfahren zu ihrer Herstellung und zu ihrer Verwendung
EP2163250B1 (en) * 2007-05-18 2013-01-09 National University Corporation Asahikawa Medical University Anticancer therapy by transplanting vascular endothelial progenitor cells
CN102154213B (zh) * 2011-01-19 2012-07-25 郑骏年 一种运载荷载细胞因子的双调控溶瘤腺病毒的新型cik细胞
JP2015506697A (ja) * 2012-02-01 2015-03-05 ポステック アカデミー‐インダストリー ファウンデーション １２量体ｔｒａｉｌ及びｈｓｖ−ｔｋ自殺遺伝子を同時に発現するベクター並びにそれを用いた抗癌幹細胞治療剤
CN103288966B (zh) * 2013-05-17 2015-01-21 华侨大学 一种融合受体及其用于治疗大肠癌的基因药物
RU2552609C1 (ru) * 2013-10-28 2015-06-10 Федеральное государственное бюджетное учреждение науки Институт молекулярной биотехнологии им. В.А. Энгельгардта Российской академии наук (ИМБ РАН) Способ получения системы направленной доставки белковых молекул (онколитических белков) в опухолевые ткани на основе активированных лимфоцитов
CA3003133C (en) 2014-10-24 2020-09-15 StemImmune, Incorporated Combination immunotherapy approach for treatment of cancer
US10906951B2 (en) * 2015-07-29 2021-02-02 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
ES2701338T3 (es) * 2015-07-29 2019-02-21 Onkimmune Ltd Células asesinas naturales modificadas y líneas de células asesinas naturales que tienen mayor citotoxicidad
CN112469816A (zh) * 2018-06-06 2021-03-09 加拿大干细胞技术公司 用于富集髓系来源的抑制细胞的试剂盒、组合物和方法
CN113677791A (zh) * 2019-03-21 2021-11-19 昂克医疗有限公司 对细胞死亡具有增加的抗性的经修饰的免疫效应细胞
EP3712257A1 (en) 2019-03-21 2020-09-23 ONK Therapeutics Limited Modified natural killer cells with increased resistance to cell death
WO2021209625A1 (en) 2020-04-17 2021-10-21 Onk Therapeutics Limited High potency natural killer cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002507117A (ja) * 1997-06-04 2002-03-05 オックスフォード・バイオメディカ・（ユーケイ）・リミテッド ベクター
EP1317288A2 (en) * 2000-09-11 2003-06-11 MUSC Foundation For Research Development Method and composition for treating tumors by selective induction of apoptosis
JP2004529102A (ja) * 2000-10-24 2004-09-24 イミュネックス・コーポレーション 併用療法を用いて、腫瘍を治療する方法
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
JP4493882B2 (ja) * 2001-06-19 2010-06-30 株式会社カネカ 抗原およびこの抗原を識別するモノクローナル抗体

Also Published As

Publication number Publication date
ZA200701231B (en) 2008-08-27
PL1771468T3 (pl) 2010-07-30
US20070264231A1 (en) 2007-11-15
DK1771468T3 (da) 2010-05-25
EP1621550A1 (en) 2006-02-01
HK1110874A1 (en) 2008-07-25
PT1771468E (pt) 2010-04-20
NZ552223A (en) 2009-01-31
EP1771468B1 (en) 2010-01-20
RU2390558C2 (ru) 2010-05-27
KR20070047757A (ko) 2007-05-07
CA2571426A1 (en) 2006-02-02
IL180233A0 (en) 2007-07-04
AU2005266543A1 (en) 2006-02-02
WO2006010558A8 (en) 2006-08-24
IL180233A (en) 2010-12-30
AU2005266543B2 (en) 2012-02-02
EP1771468A1 (en) 2007-04-11
JP5042826B2 (ja) 2012-10-03
BRPI0513855A (pt) 2008-05-20
JP2008507961A (ja) 2008-03-21
NO20070956L (no) 2007-02-20
MX2007001152A (es) 2007-04-18
CN101076540B (zh) 2012-10-24
SI1771468T1 (sl) 2010-07-30
WO2006010558A1 (en) 2006-02-02
DE602005019050D1 (de) 2010-03-11
RS51381B (en) 2011-02-28
ES2340400T3 (es) 2010-06-02
CN101076540A (zh) 2007-11-21
RU2007107369A (ru) 2008-09-10
ATE455847T1 (de) 2010-02-15

Similar Documents

Publication Publication Date Title
HRP20100227T1 (hr) Stanice domaćini tumora preuređene da proizvode ligand koji inducira apoptozu povezanu s faktorom nekroze tumora (trail)
Ahn et al. Human adipose tissue-derived mesenchymal stem cells inhibit melanoma growth in vitro and in vivo
Wang et al. BMP-2 inhibits tumor-initiating ability in human renal cancer stem cells and induces bone formation
Yang et al. Celastrol inhibits cancer metastasis by suppressing M2-like polarization of macrophages
Kamalabadi-Farahani et al. Anti-tumour effects of TRAIL-expressing human placental derived mesenchymal stem cells with curcumin-loaded chitosan nanoparticles in a mice model of triple negative breast cancer
JP2008507961A5 (ja)
Lu et al. A new 3D organotypic model of ovarian cancer to help evaluate the antimetastatic activity of RAPTA-C conjugated micelles
CN111888376B (zh) 一种负载顺铂的纤维蛋白胶复合体系联合治疗系统
Gotoh et al. Antitumor action of α1-adrenoceptor blockers on human bladder, prostate and renal cancer cells
Cheung et al. Characteristics of a low‐molecular‐weight factor extracted from mouse tumors that affects in vitro properties of macrophages
Li et al. Mesenchymal stem cells in gastric cancer: vicious but hopeful
Wang et al. Nanobiotechnological Nanocapsules Containing Polyhemoglobin‐Tyrosinase: Effects on Murine B16F10 Melanoma Cell Proliferation and Attachment
Abd et al. Hypoxia-induced cancer cell reprogramming: a review on how cancer stem cells arise
Chen et al. In-situ-sprayed therapeutic hydrogel for oxygen-actuated Janus regulation of postsurgical tumor recurrence/metastasis and wound healing
CN103816535B (zh) 一种肿瘤疫苗及其制备方法
CN106188244B (zh) 抑制癌细胞活性的短肽治疗剂及含有它的医药组合物
CN103861107A (zh) 一种药物组合物及其用途
CN109939127A (zh) Nk细胞的应用及包括该nk细胞的药物组合物及其应用
CN106075453A (zh) 一种抗肿瘤药物制剂组合
Huang et al. Evidence that high-migration drug-surviving MOLT4 leukemia cells exhibit cancer stem cell-like properties
BRPI0707247B8 (pt) vacina para tumor compreendendo células tumorais alogênicas ou xenogênicas
CN101744848B (zh) Fhl3在制备用于治疗肿瘤的药物中的用途
CN101683518B (zh) Fhl1在制备用于治疗肿瘤的药物中的用途
Lyu et al. Halogen-bridged binuclear iridium (iii) complexes with enhanced photodynamic therapeutic effects in mitochondria
Wang et al. Platinum nanoparticles enhance osteogenic differentiation of human dental follicle stem cells via scavenging ROS